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Abstract
Adverse drug events (ADEs) are a common cause of patient morbidity and mortality and are 
classically thought to result, in part, from variation in expression and activity of hepatic enzymes 
of drug metabolism. It is now known that alterations in the expression of genes that encode drug- 
and bile-acid–transporter proteins in both the gut and liver play a previously unrecognized role in 
determining patient drug response and eventual clinical outcome. Four nuclear receptor (NR) 
superfamily members, including pregnane X receptor (PXR, NR1I2), constitutive androstane 
receptor (NR1I3), farnesoid X receptor (NR1H4), and vitamin D receptor (NR1I1), play pivotal 
roles in drug- and bile-acid– activated programs of gene expression to coordinately regulate drug- 
and bile-acid transport activity in the intestine and liver. This review focuses on the NR-mediated 
gene activation of drug and bile-acid transporters in these tissues as well as the possible 
underlying molecular mechanisms.
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Introduction
It is well recognized that a significant portion of adverse drug events (ADEs) in the clinical 
setting are the result of the atypical metabolism of drugs (Wilkinson, 2005). A more-recent 
thrust of research has focused on the identification of aberrant transport of clinically 
prescribed drugs resulting from alterations in expression and activity of drug- and bile-acid–
transporter proteins in the gut and liver (Tirona, 2011). It is worth noting that many of the 
metabolic enzymes and transporter proteins that act on drugs also metabolize and transport 
bile acids into and out of these tissues. Moreover, a small group of ligand-activated 
transcription factors that “sense” the presence of drugs and bile acids has coevolved to 
regulate their expression and maintain a level of homeostasis.
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The molecular mechanisms governing the drug- and bile-acid–inducible expression of genes 
that encode drug- and bile-acid–transporter proteins are well described, and it is now clear 
that several members of the nuclear receptor (NR)1 subfamily of the NR superfamily are 
key mediators of their expression in the enterohepatic system. Perturbations in the lines of 
communication between these two tissues during pathological conditions lead to the aberrant 
transport and metabolism of clinically prescribed drugs in patients. In particular, four 
different ligand-activated NR transcription factors, including pregnane X receptor (PXR, 
NR1I2), constitutive androstane receptor (CAR, NR1I3), farnesoid X receptor (FXR, 
NR1H4), and vitamin D receptor (VDR, NR1I1), directly regulate the inducible expression 
of genes in enterohepatic tissue that encode pivotal drug- and bile-acid– transporter proteins 
(Figure 1).
This review considers the coordinate regulation of both drug and bile-acid transporters by 
members of the NR superfamily and highlights recent research efforts that focus on the 
molecular mechanisms underlying the gene expression that directly affect the uptake and 
efflux of drugs and bile acids in these tissues.
NR regulation of genes encoding drug and bile-acid transporters
Among the NR target genes that encode transporter proteins considered in this review, most 
have been characterized as transporters of both endogenous and xenobiotic compounds and 
can be classified as either uptake or efflux transporters. The uptake transporters discussed 
are members of the solute carrier organic anion transporter (SLCO) family (organic anion 
transporter polypetides; OATPs) or the solute carrier (SLC) family [sodium taurocholate 
cotransporting polypeptide (NTCP) and apical sodium-dependent bile-acid transporter 
(ASBT)]. These transporters have a vast array of endo- and exogenous substrates and 
function in the cellular uptake of organic ions, xenobiotics, and bile acids from the lumen of 
the intestine and from portal circulation into hepatocytes (Table 1). The efflux transporters 
that will be discussed are mainly members of the adenosine triphosphate (ATP)-binding 
cassette (ABC) superfamily, with the exception of organic solute transporters (OSTs), and 
function in the efflux and excretion of many of the same xenobiotics, as well as endogenous 
molecules that are substrates for uptake transporters (Table 2). The coordinating uptake and 
efflux functions of these transporters allow the body to maintain a level of homeostasis by 
regulating the expression of the genes that encode these transporters under healthy 
physiological and pathological states. This section discusses the regulation of uptake and 
efflux transporters by the previously mentioned members of the NR superfamily. This 
review focuses on regulation of drug and bile-acid transporters in relevant human model 
systems; however, wherever distinct species differences exist, we include references to the 
appropriate rodent systems.
Uptake transporters
Organic anion transporting polypeptide family member 1A2 (OATP1A2)
OATP1A2 is responsible for the uptake of a wide variety of endo- and exogenous substrates 
from the intestinal lumen as well as from the portal circulation. Several reports indicate that 
the expression of OATP1A2 is induced by PXR activators in breast cancer cells and cultured 
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hepatocytes (Meyer zu Schwabedissen et al., 2008; Miki et al., 2006; Oscarson et al., 2006). 
Using human-derived cell lines (MCF-7, T47-D, HeLa, and HepG2), as well as malignant 
and adjacent nonmalignant human breast tissue samples, promoter analysis indicates that 
this effect is the result of direct regulation by PXR (Meyer zu Schwabedissen et al., 2008). 
Direct interaction between PXR, a major xenobiotic sensing NR, and the OATP1A2 
promoter indicates the possibility of a regulatory pathway that is designed to increase the 
uptake of xenobiotics, therefore increasing the body’s ability to conjugate and excrete drugs. 
Recent reports also implicate VDR in the ligand-dependent transactivation of OATP1A2 
using Caco-2 cells derived from human colon carcinoma. These studies show a significant 
increase in the expression of OATP1A2 messenger RNA (mRNA) after 24-hour treatment 
with 500 nM of vitamin D3 as well as after treatment of 50 μM of lithocholic acid (LCA), a 
VDR agonist, which was attenuated after small interfering RNA (siRNA)-mediated 
knockdown of VDR. This study also demonstrated an increase in OATP1A2 protein levels 
after 8 hours of treatment with vitamin D3 (Eloranta et al., 2012). Taken together, these data 
strongly implicate VDR in the regulation of OATP1A2 in a manner that parallels PXR-
mediated regulation in human model systems.
OATP1B1
OATP1B1 is also involved in the uptake of numerous endogenous substrates as well as 
several clinically important drugs, such as statins, olmesartan, and methotrexate, from the 
portal circulation (Hirano et al., 2004). Because OATP1B1 is a high-affinity sinusoidal 
transporter for rifampicin, a well-known prototypical PXR activator, this highlights a unique 
mode of interplay by serving as the rate-limiting determinant of PXR-mediated gene 
activation (Gui et al., 2008; Tirona et al., 2003). Although there are not strong data 
implicating PXR in direct gene regulation of OATP1B1, two reports suggest that treatment 
of seven independent human hepatocyte cultures with PXR ligands, such as rifampicin, led 
to a moderate increase in mRNA expression (Jigorel et al., 2006; Oscarson et al., 2006). 
Using the human hepatoma Huh-7 cell line, FXR has been clearly demonstrated to be a 
direct, major regulator of OATP1B1 expression in response to treatment with the human 
FXR bile-acid activator, chenodeoxycholic acid (CDCA) (Meyer Zu Schwabedissen et al., 
2010). The fact that many substrates of OATP1B1 are also ligands for the NRs that regulate 
expression of this transporter reveals a feedback loop that functions to maintain the 
homeostatic condition. It is interesting to note that atorvastatin, cerivastatin, and fluvastatin, 
which are all OATP1B1 substrates, can also activate CAR (Meyer zu Schwabedissen and 
Kim, 2009). Though there is currently no direct evidence supporting the regulation of 
OATP1B1 by CAR, it is formally possible that this uptake transporter is regulated in an 
overlapping, yet distinct, manner by CAR, PXR, and FXR cross-talk.
OATP1B3
OATP1B3 is another liver-specific member of the organic anion transporter family that 
mediates the sodium-independent uptake of many xenobiotic compounds. The OATP1B3 
transporter protein also plays a critical role in bile-acid and bilirubin transport. In fact, 
mutations in this gene are a cause of Rotor type hyperbilirubinemia, a disease that leads to 
an increase in conjugated bilirubin in serum (van de Steeg et al., 2012). The bile acid, 
CDCA, and strong activator of human FXR induces the expression of OATP1B3 promoter 
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activity in human hepatoma HepG2 and Huh7 cell lines, which is consistent with this OATP 
bile-acid–transporting function (Jung et al., 2002b). This same study showed that direct 
binding of FXR to an identified FXR-response element in the upstream promoter region of 
the gene encoding OATP1B3 is required for induction by bile acids in these human cell 
lines. Two separate reports indicated that treatment of human hepatocytes (Jigorel et al., 
2006) or liver slices (Olinga et al., 2008) with rifampicin, a strong human PXR activator, 
reduced the expression level of OATP1B3. It is important to note that although both 
OATP1B1 and OATP1B3 exhibit similar substrate selectivities and are similarly localized 
on the basolateral membrane of hepatocytes, they are regulated in an opposing manner after 
activation of human PXR with rifampicin. The molecular mechanisms that produce 
downregulation of OATP1B3 are not currently known, though competition for transcription-
factor–associated coactivator proteins represents a potential mechanism. The functional and 
biological significance of opposing regulation of these two OATP family members after 
PXR activation also remains to be determined; however, it is tempting to speculate that this 
is a physiological compensatory mechanism used to maintain xenobiotic homeostasis during 
pharmacological treatment with PXR agonists.
NTCP
NTCP, sometimes called the liver bile-acid transporter, is expressed in the basolateral 
membrane of hepatocytes, where it functions as the primary uptake transporter of conjugated 
and unconjugated bile acids under healthy physiological conditions. When cholestatic 
conditions are experimentally produced using common bile-duct ligation (BDL) in rats and 
bile acids accumulate in serum and liver, NTCP expression is rapidly downregulated 
(Gartung et al., 1996). This may be a mechanism that limits the hepatic uptake of bile acids 
and prevents subsequent hepatotoxicity. Downregulation of NTCP in primary rat 
hepatocytes, as well as in human HepG2 and monkey Cos1 cell lines, is mediated by an 
indirect mechanism involving bile acid/FXR-mediated induction of a dominant-negative 
atypical NR called small heterodimer partner (SHP) (Denson et al., 2001). In this way, 
induction of SHP expression by FXR is thought to downregulate NR-mediated 
transactivation of the promoters of key genes whose gene products are pivotal regulators of 
bile-acid homeostasis, including NTCP, as well as cholesterol 7α hydroxylase (CYP7A1), 
the rate-limiting enzyme in the conversion of cholesterol to bile acids (Denson et al., 2001; 
Goodwin et al., 2000).
ASBT
The intestinal counterpart to NTCP is the ileal sodium/bile-acid cotransporter (ASBT or 
IBAT). This transporter is the primary mediator of bile-acid uptake from the lumen of the 
intestine. Because bile acids are the catabolic product of cholesterol metabolism, both NTCP 
and ASBT are critically important for cholesterol homeostasis. In humans, a loss-of-function 
mutation in SLC10A2, the gene that encodes ASBT, causes fatty diarrhea, fat malabsorption, 
and malnutrition (Oelkers et al., 1997; Wong et al., 1995). As with NTCP, activation of FXR 
with CDCA in the Caco-2 cell line indirectly induces negative feedback regulation of human 
ASBT by an FXR-mediated/SHP-dependent effect upon expression of ASBT in the intestine 
(Neimark et al., 2004). Though there is no biochemical evidence implicating PXR and CAR 
in the direct regulation of human ASBT, it has been shown that atorvastatin delivered to 
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mice in a 0.1% enriched diet over 7 days significantly increased the expression of mouse 
Asbt mRNA (Wagner et al., 2005). Although it is possible that atorvastatin directly activates 
PXR/CAR to upregulate the expression of Asbt, a more-likely explanation comes from the 
fact that this statin upregulates the expression of the NR family member, peroxisome 
proliferator-activated receptor alpha (PPAR-α) (Roglans et al., 2002), which is a potent, 
direct regulator of ASBT in human model systems (Jung et al., 2002a).
Efflux transporters
Multidrug Resistance Protein 1/P-Glycoprotein (MDR1/P-gp)
MDR1, also commonly known as P-gp, is a major efflux transporter that is primarily 
responsible for the rapid “inside-out” efflux of a vast majority of xenobiotics. Therefore, 
MDR1/P-gp plays a major role in decreased drug accumulation in multidrug-resistant cells 
and is associated with drug bioavailability (Kurata et al., 2002; Siegmund et al., 2002a, 
2002b). Overexpression of MDR1/P-gp mediates the development of resistance to 
anticancer drugs in certain tumor types (Juranka et al., 1989). NR-mediated regulation of 
MDR1/P-gp by PXR was demonstrated approximately 20 years ago. Data published by 
Schuetz et al. showed that treatment of a colon adenocarcinoma cell line with several 
clinically prescribed drugs, including the PXR activator, rifampicin, was found to increase 
the expression and activity of MDR1/P-gp (Schuetz et al., 1996). Another study showed an 
increase in MDR1/P-gp protein expression, which directly corresponded with a decrease in 
levels of digoxin, a MDR1/P-gp substrate, upon administration of rifampin, a strong PXR 
agonist (Greiner et al., 1999). Because of the overlapping regulatory functions of PXR and 
CAR, it was also hypothesized that CAR may regulate the expression of MDR1/P-GP. 
Subsequent studies found that NRs PXR and CAR directly regulate expression of the MDR1 
gene through an immediate upstream promoter element exclusively in the intestine (Burk et 
al., 2005; Geick et al., 2001). A more-recent study showed induction of MDR1/P-gp mRNA 
expression after treatment with rifampicin and phenobarbital, a CAR agonist, in primary 
cultures of human hepatocytes (Jigorel et al., 2006). There is also evidence implicating VDR 
in the regulation of MDR1/P-gp. One study showed that treatment with vitamin D induced 
high levels of expression of MDR1/P-gp in the intestinal adenocarcinoma cell line, Caco-2 
(Schmiedlin-Ren et al., 1997). A more-recent study showed significant induction of 
MDR1/P-gp protein and mRNA expression after treatment with 100 nM of 1α,25-
dihydroxyvitamin D3 (1,25(OH)2D3) in the human colon carcinoma cell line, LS180 (Aiba 
et al., 2005). Successive studies from the same research group identified multiple functional 
VDR response elements in the promoter of the human MDR1 gene, which collectively 
contributed to gene expression (Saeki et al., 2008).
OSTα/OSTβ
Organic solute transporters -alpha and -beta (OSTα/OSTβ) form a heterodimeric efflux 
transporter that is expressed at relatively high levels on the basolateral membranes of 
enterohepatic tissue. Its primary function is the efflux of bile acids into the portal circulation 
from both enterocytes and hepatocytes, making it an essential mediator of bile-acid 
homeostasis in the enterohepatic circulation (Ballatori et al., 2005; Dawson et al., 2005). 
The regulatory effects of OSTα/OSTβ on bile-acid homeostasis make this transporter a 
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plausible target of FXR-mediated regulation, and there are many studies to support this. One 
study showed induction of human OSTα/OSTβ mRNA in two different human hepatoma 
cell lines (Huh7 and HepG2) after treatment of cells with both endogenous (50 μM of 
CDCA) and exogenous (200 nM of GW4064) FXR ligands. This induction is directly 
attributed to FXR because of the fact that knockdown of FXR using siRNA attenuated the 
ligand-mediated induction (Landrier et al., 2006). Another study performed by a separate 
research group showed induction of OSTα/OSTβ mRNA after 24-hour treatment with 
CDCA in the human hepatoma HepG2 cell line, HepG2. The same group showed significant 
increases in protein and mRNA levels of OSTα and OSTβ in patients with primary biliary 
cirrhosis, a disease resulting in blockage of bile flow caused by chronic inflammation of the 
bile duct. There is also evidence to support the regulation of OSTα/OSTβ by VDR. One 
study found that treatment with 50 μM of CDCA and 5–10 μM of LCA, both of which are 
VDR agonists, increased the expression of OSTα/OSTβ in human ileum and liver slices 
(Khan et al., 2009). However, because of the fact that 1,25(OH)2D3 had no effect on 
transporter expression, and that both CDCA and LCA are also agonists of FXR, it is unclear 
whether this increase can be completely attributed to VDR or is perhaps a ligand-specific 
effect.
Multidrug resistance-associated protein 2 (MRP2)
MRP2 is an efflux transporter protein responsible for the removal of conjugated xenobiotics 
and bile acids from the liver into bile. Because of its wide substrate selectivity and pivotal 
excretory function on apical membranes in hepatocytes, it is interesting to note that 
expression of this efflux transporter is coordinately regulated by multiple NRs that function 
as both xenobiotic and bile-acid sensors. Regulation of MRP2 expression by PXR, FXR, and 
CAR was originally described in human, mouse, and rat hepatocytes in 2002. This study 
showed induction of MRP2 mRNA after treatment with agonists of FXR, PXR, and CAR 
(Kast et al., 2002). Additional studies implicated both PXR and FXR as positive regulators 
of MRP2 expression and activity in the intestine (Cheng and Klaassen, 2006; Zollner et al., 
2003). A recent study revealed that ortho-aminoazotoluene, a possible (class 2B) human 
carcinogen, activates CAR to upregulate MRP2 expression in mouse liver in a CAR-
dependent manner (Smetanina et al., 2011). Though there is no direct evidence showing 
VDR-mediated regulation of human MRP2, a recent study shows a significant increase in rat 
Mrp2 protein expression after intraperitoneal injection of 1,25(OH)2D3 at a dose of 0.64 
nmol/kg/day (Chow et al., 2010). Taken together, these studies suggest that PXR, CAR, 
VDR, and FXR upregulate protein and mRNA expression of MRP2 in response to distinct 
ligands to increase rate of efflux and/or biliary elimination of numerous organic anions, thus 
providing a mechanism to enhance excretion of these compounds from the body.
MRP3
MRP3 is an efflux transporter that functions in the removal of exo- and endogenous 
compounds from hepatocytes into the blood. Though the tissue localization and transporter 
function of MRP3 is well-known, its specific substrates have only recently been well 
characterized. They include methotrexate, acetaminophen (APAP) glucuronide, APAP 
sulphate, bilirubin, estradiol-17β-glucuronide, ritonavir, sequinavir, conjugated cholic acid 
(CA), and several other endogenous and xenobiotic compounds (Keppler, 2011; Meijerman 
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et al., 2008). It has been shown that treatment with 5–10 μM of LCA significantly induces 
the expression of MRP3 mRNA in human ileum slices, implicating a regulatory role for 
FXR and/or VDR at the transcriptional level (Khan et al., 2011). Regulation of MRP3 
expression by PXR and CAR in the liver was demonstrated in mice (Staudinger et al., 2003), 
and a subsequent study further implicated a complimentary and combined role for PXR, 
FXR, and CAR in protecting against bile-acid–induced hepatotoxicity, in part resulting from 
induction of MRP3 expression and activity in the liver (Guo et al., 2003). Robust 
information demonstrating the transcriptional regulation of human MRP3 by PXR is 
currently lacking. However, one study examined the relationship between PXR and MRP3 
in human colon cancer chemoresistance. The investigators used reverse-transcriptase 
polymerase chain reaction and western blot analysis to demonstrate that mRNA expression 
and protein levels of PXR and MRP3 were much higher in colon cancer tissues than that 
found in non-neoplastic tissues (Jiang et al., 2009). More research is necessary to determine 
the extent to which this transporter protein is differentially regulated by NRs in human liver 
and intestine.
MRP4
MRP4 is an efflux transporter that transports several clinically prescribed drugs, such as 
adefovir, cefazolin, ceftizoxime, furosemide, irinotecan, leucovorin, methotrexate, and 
topotecan. Conjugated divalent sulphated and monovalent bile acids are also substrates for 
this transporter (Keppler, 2011; Meijerman et al., 2008). It has been shown that expression 
of MRP4 undergoes adaptive upregulation in response to cholestatic injury or bile-acid 
feeding (Zollner et al., 2003), and CAR has been implicated in the regulation of MRP4 in 
several studies. One study performed using CAR knockout mice indicated that CAR is 
required for induction of MRP4 in the liver after treatment with 1,4-bis-[2-(3,5-
dichloropyridyloxy)]benzene, 3,3′,5,5′-tetrachloro-1,4-bis(pyridyloxy)benzene (Aleksunes 
and Klaassen, 2012), followed by experimental data from another research group 
demonstrating that CAR activators increase MRP4 expression in primary human 
hepatocytes and HepG2 cells (Assem et al., 2004). Chai et al. demonstrated a significant 
increase in MRP4 mRNA levels in patients suffering from obstructive cholestasis. This same 
investigation established a statistically positive correlation between MRP4 mRNA levels 
and CAR protein levels, suggesting that CAR may positively regulate MRP4 transcriptional 
activity in an effort to increase bile-acid efflux in hepatic injury (Chai et al., 2011). A 
different group demonstrated an increase in MRP4 mRNA in patients suffering from 
alcoholic liver disease, chronic hepatitis C infection, and primary sclerosing cholangitis, 
which correlated with a decrease in CAR, PXR, and RXRα mRNA levels. Data pertaining to 
CAR mRNA levels are consistent with those found in the previously discussed research by 
Chai et al., but protein expression levels were not examined in this study. More recently, a 
negative role for FXR in the regulation of MRP4 has been hypothesized. Renga et al. 
demonstrated that FXR negatively regulates MRP4 both in vivo and in vitro. Data from this 
study showed that treatment of HepG2 cells with CDCA, CA, and the synthetic FXR 
activator, GW4064, suppressed basal mRNA levels of MRP4 and inhibits the CAR-
mediated induction of MRP4 expression by 6-(4-chlorophenyl)imidazol[2,1-b] 
[1,3]thiazole-5-carbaldehyde-O-(3,4-dicholorobenzyl) oxime. The investigators also 
Staudinger et al. Page 7













demonstrate that deletion of FXR in vivo leads to an increase in basal expression levels of 
MRP4 (Renga et al., 2011).
Breast Cancer Resistance Protein (BCRP)
BCRP functions as a xenobiotic transporter to mediate excretion of its substrates and thus 
influences the pharmacokinetics of many drugs. For example, BCRP serves as a cellular 
defense mechanism in response to mitoxantrone, anthracycline, and methotrexate exposure 
in multiple cell lines (Allen and Schinkel, 2002; Doyle and Ross, 2003). BRCP also 
transports sulfoconjugated organic anions, such as estrone 3-sulfate. One of the main 
expression sites for BCRP is the placenta, where it is expressed at the apical membrane of 
syncytiotrophoblasts. In the placenta, BCRP is likely involved in the transport of its 
substrates from fetal to maternal blood, thereby playing a protective role for the fetus by 
transporting toxic compounds from fetal circulation into maternal circulation for eventual 
excretion. Conflicting information exists regarding the regulation of BCRP by PXR and 
CAR. Early studies using primary cultures of human hepatocytes indicated that PXR 
activators increased the expression of BCRP (Jigorel et al., 2006; Oscarson et al., 2006). 
More-recent studies indicate that PXR and CAR activators do not regulate the expression of 
this transporter in rodent liver (Aleksunes and Klaassen, 2012). Mice engineered to lack 
PXR exhibit increased expression of BCRP in the placenta, though it is not clear whether 
this is a direct effect, because PCN did not induce BCRP expression (Gahir and Piquette-
Miller, 2011). Therefore, more research is necessary to determine the extent to which this 
transporter is under the regulation of NRs in hepatocytes and placenta.
Bile Salt Excretory Pump (BSEP)
BSEP is the major canalicular (apical) bile-salt export pump in mammals. Mutations in the 
gene that encodes this transporter will cause progressive familial intrahepatic cholestasis, a 
severe, often lethal disease characterized by cholestatic liver disease and eventual liver 
failure beginning from early infancy. The primary NR regulator of BSEP is FXR. FXR has 
been shown to directly regulate the expression of BSEP by binding to its proximal promoter 
and is transactivated by the FXR activator, CDCA (Ananthanarayanan et al., 2001; Schuetz 
et al., 2001). Although PXR, CAR, and VDR are not known to directly regulate BSEP 
expression in hepatocytes, more research is necessary to determine the interactions between 
these signaling pathways, because treatment with PXR ligands causes a significant decrease 
in expression of BSEP in primary cultures of human hepatocytes (Jigorel et al., 2006). The 
NR superfamily member liver receptor homolog 1 (LRH-1) is required for maximal hepatic 
expression of CYP7A1 and was recently shown to play a supporting role, together with 
FXR, in maintaining hepatic bile-acid levels by coordinately regulating both CYP7A1 and 
BSEP expression and activity for bile-acid synthesis and elimination (Song et al., 2008). 
Interestingly, SHP-mediated repression of BSEP was subservient to FXR-mediated 
activation toward BSEP, thus bile acids downregulate CYP7A1 to decrease bile-acid 
production, whereas, at the same time, they increase BSEP expression and activity to 
increase bile-acid elimination from the liver. Differential downregulation of liver-enriched 
FXR-target genes can likely be explained by differences in cell-signaling pathways and the 
presence of a newly discovered gut-liver axis.
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NR cross-talk and disruption in the gut-liver axis
It is physiologically important to maintain strict control of serum bile-acid levels because 
accumulation of these compounds in blood and/or cells can produce profound 
hepatotoxicity. Moreover, infection with certain viruses and bacteria can produce severe 
liver disease that is often a result of chronic inflammation, which can inhibit the normal 
function of regulatory NRs. Communication between NRs can have differential effects on 
the genes being regulated, thus understanding the cross-talk that occurs between NRs is 
critical in the discovery of novel strategies to combat pathological conditions and ADEs in 
the clinic as well as in the development of new pharmaceutical agents. Below, we focus on 
the cross-talk between the previously discussed regulatory NRs as well an emerging 
molecular circuit involving NR cross-talk that is highly implicated in drug- and bile-acid 
transporter regulation.
NR cross-talk in enterohepatic tissue
NR cross-talk in relation to the regulation of enterohepatic transporters can come in several 
forms: competitive cross-talk; inhibitory cross-talk; and noncompetitive cross-talk. This is a 
relatively new field, but there are still multiple studies to support all three ideas. Multiple 
studies have shown that PXR, CAR, and VDR all compete for the same response elements 
on the promoter of CYP2A4 (Pascussi et al., 2005; Moreau et al., 2007), demonstrating the 
notion of competitive NR cross-talk. Another research group has also suggested the concept 
of competitive cross-talk between CAR and FXR. Analysis of the MRP4 promoter revealed 
the presence of a CAR-responsive element embedded within the FXR response element, 
suggesting that FXR and CAR compete for binding and that FXR could hinder the 
protective effects modulated by CAR activation in disease states (Renga et al., 2011). There 
is also evidence that supports inhibitory cross-talk, in which the activation of one NR leads 
to the suppression of another. One study showed that PXR transcriptional activity is 
hindered by the presence of SHP, an NR that is upregulated in the FXR/SHP-mediated 
regulatory mechanism (Ourlin et al., 2003). Noncompetitive cross-talk often occurs between 
CAR and PXR. These two NRs are closely related and have a large subset of overlapping 
ligands. Studies show that in the absence of both PXR and CAR, the CAR ligand, 
Phenobarbital, will activate another liver-enriched NR: PPAR-α (Tamasi et al., 2009). NR 
cross-talk is an important part in the regulation of transporters as well as in the 
understanding of xenobiotic uptake, metabolism, and clearance. The fact that different NRs 
can regulate distinct and overlapping groups of target genes and can be activated by 
common, as well as individual, ligands suggests that NRs communicate to simultaneously 
maintain homeostatic conditions, depending upon cellular needs. These cellular needs could 
include xenobiotic uptake and clearance, compensation for a defective protein or regulatory 
cascade, or protection from drug and bile-acid accumulation. The fact that NR cross-talk 
aids in the regulation of xenobiotic clearance is an important notion in the effort of 
researchers to eliminate ADEs and drug-drug interactions (DDIs) in clinical and personal 
settings. According to the IMS Institution for Healthcare Informatics, simvastatin was the 
second-most prescribed medication (94.1 million prescriptions) in early 2011 (http://
www.webmd.com/news/20110420/the-10-most-prescribed-drugs), and, as shown in Tables 
1 and 2, it is also a substrate for previously discussed uptake and efflux transporters as well 
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as certain NRs. This one medication is known to have 213 drug interactions, ranging from 
slight to severe, in the healthy individual (http://www.drugs.com/drug-interactions/
simvastatin.html). The fact that this popular medication is also known to have potentially 
life-threatening hepatotoxic effects, if drug metabolism by the liver is even slightly 
compromised, also furthers the need to elucidate the full mechanism behind NR cross-talk 
and transporter regulation. Discovering the mechanism by which the body partially or totally 
compensates for the loss or malfunction of a xenobiotic transporter or regulatory NR in both 
healthy and pathological states could possibly aid in the development of novel strategies to 
prevent ADEs in the clinical setting.
An FXR/SHP-mediated mechanism of drug- and bile-acid–transporter 
regulation
A prime example of NR communication is presented in the FXR-SHP regulatory pathway. 
In the liver and intestine, activation of FXR induces expression of SHP. The SHP protein, in 
turn, represses expression of CYP7A1 by inhibiting the activity of LRH-1 (Figure 2). This 
FXR-mediated regulatory cascade provides, in part, the molecular basis for the coordinate 
suppression of CYP7A1 and other genes involved in bile-acid biosynthesis and transport 
including, NTCP (Goodwin et al., 2000; Lu et al., 2000). Consistent with this model, mice 
genetically engineered to lack the SHP gene exhibited defects in bile-acid homeostasis and 
failed to repress CYP7A1 expression in response to a pharmacological FXR activator, 
GW4064 (Wang et al., 2002). However, repression of CYP7A1 expression is retained in 
SHP-null mice fed bile-acid activators (e.g., CA) of FXR, suggesting an intestine-specific 
effect. Other studies showed that BDL, or decreased bile acids in the intestine, paradoxically 
increased CYP7A1 in livers of rats (Dueland et al., 1991; Gustafsson, 1978). Hepatic bile 
acid levels increase under these conditions, thus further suggesting a role for the intestine in 
feedback repression of bile-acid synthesis. Still, other studies have shown that direct 
administration of bile acids into the intestine inhibited CYP7A1 expression; in contrast, 
administration of bile acids intravenously or directly into the portal circulation did not 
(Nagano et al., 2004; Pandak et al., 1991). Collectively, these observations led to the 
hypothesis that a functionally redundant pathway for CYP7A1 repression, involving a 
previously unknown gut-liver–signaling pathway, exists. Recently, this hypothesis was 
proven true and resulted in the identification of a novel gut-liver axis involving bile-acid–
mediated induction of the expression of fibroblast growth factor family member 15 (FGF15) 
(Reviewed in Potthoff et al., 2012).
Expression of FGF15 is stimulated in the small intestine by bile-acid activation of FXR and 
acts in an endocrine manner to repress CYP7A1 expression in the liver through a 
mechanism that involves FGF receptor 4 (FGFR4) and SHP (Figure 3). Mice lacking the 
gene encoding FGF15 exhibited increased hepatic CYP7A1 mRNA and protein levels and 
corresponding increases in CYP7A1 enzyme activity and fecal bile-acid excretion (Inagaki 
et al., 2005). These studies defined FGF15 and FGFR4 as key components of a gut-liver axis 
that synergizes with SHP to regulate bile-acid synthesis by CYP7A1. Interestingly, 
activation of the VDR in mice produced similar effects and has been attributed to increased 
intestinal absorption of bile acids through increased ASBT-mediated transport of bile acids 
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in the ileum and subsequent elevated levels of FGF15, events that led to the activation of 
FXR in the liver (Chow et al., 2009). FXR-mediated induction of BSEP removes bile acids 
from the liver (Ananthanarayanan et al., 2001), whereas hepatic uptake of bile acids is 
slowed by SHP-mediated repression of NTCP (Denson et al., 2001). Thus, during 
cholestasis, the liver is protected from injury by potentially toxic levels of accumulating bile 
acids in serum. Future research should focus on determining the extent to which FGF-
mediated repressive signaling pathways alter expression levels of other drug- and bile-acid–
transporter proteins in the liver and intestine, especially during pathological conditions, such 
cholestasis and inflammatory liver and bowel disease.
Conclusions
Although the role of liver- and gut-enriched NR proteins PXR, CAR, FXR, and VDR in the 
regulation of drug-metabolizing enzymes has been well established, the challenge remains to 
accurately assess the role of these ligand-activated transcription factors in the regulation of 
drug and bile-acid transporters in these tissues during specific pathological conditions. 
Recent advances in knowledge regarding identification of ligands for these important NRs, 
as well as identification of novel regulatory circuits that coregulate drug-metabolizing 
enzymes and transporter proteins to affect both drug and bile-acid disposition, are positive 
steps toward providing novel paradigms that can be exploited clinically. The ability to better 
understand how these molecular circuits function during disease states is likely to provide 
opportunities to develop novel strategies for targeting NRs during certain pathologies, such 
as cholestatic liver disease and inflammatory bowel or liver disease. For example, a recent 
study used combination bezafibrate/ursodeoxycholic acid (UCDA) therapy as an 
experimental treatment of patients presenting with cholestatic liver disease resulting from 
early primary biliary cirrhosis (Honda et al., 2012). In addition to the significant 
improvement of serum biliary enzymes, immunoglobulin M, cholesterol, and triglyceride 
concentrations in patients treated with this combination therapy, a reduction of 7α-
hydroxy-4-cholesten-3-one, a marker of bile-acid synthesis, and increase of 4β-
hydroxycholesterol, a marker of CYP3A4/5 activity, were observed. Moreover, using cell-
based analysis, the investigators of this study observed a downregulation of CYP7A1, 
CYP27A1, and NTCP and an upregulation of CYP3A4, MDR1, and MRP2 after 
combination bezafibrate/UCDA treatment.
An appreciation for the existence of a gut-liver axis that regulates bile-acid disposition is a 
major leap forward in our understanding of the biological links between drug and bile-acid 
transport and drug metabolism in these tissues. It remains to be immediately determined 
whether drug- and bile-acid–transporter proteins are under the same FGF15/19-mediated 
regulation as enzymes of bile-acid synthesis in these tissues. In the future, patients who 
present with cholestatic liver disease and inflammatory bowel or Crohn’s disease will likely 
benefit from these discoveries as new strategies for targeting these diseases emerge. We are 
just beginning to understand the relationship between NRs and drug and bile-acid 
metabolism and transport in these tissues, and until a thorough understanding of these 
relationships is achieved we will likely be unable to significantly diminish the occurrence of 
ADEs, DDI, and disease-drug interaction. We should look forward to maximizing the 
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pharmacological opportunities that are likely to be presented from this novel thrust of 
research.
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NRs act as sensors in the regulation of enterohepatic drug transporters. Drugs and bile acids 
enter enterohepatic circulation by intestinal uptake transporters (e.g., ASBT). In many cases, 
these molecules are immediately transported back into the intestinal lumen by apical efflux 
transporters (e.g., MDR1, MRP2, and BCRP). Molecules that remain within the enterocyte 
can either serve as ligands to resident NRs, such as PXR, CAR, VDR, and FXR (bottom 
figure), or are effluxed into the portal circulation by sinusoidal efflux transporters (e.g., 
MRP3). After efflux to the portal vein, drugs and bile acids travel to the liver, where they 
are transported into hepatocytes by sinusoidal uptake transporters (e.g., OATPs and NTCP). 
Once inside hepatocytes, these molecules are either excreted into the bile canaliculus by 
canalicular efflux transporters (e.g., BSEP, MDR1, BCRP, and so forth) or serve as ligands 
to resident NRs, such as PXR, CAR, and FXR (top figure). Activation of these NRs in both 
the liver and intestine leads to their heterodimerization with RXRα. This NR/RXRα 
heterodimer, which is now bound to chromatin, initiates transcription of NR-specific target 
genes, including phase I and II drug-metabolizing enzymes as well as the drug transporters 
involved in uptake and efflux of NR-specific ligands (e.g., bile acids, drugs, and so forth). 
This drug-and bile-acid–induced regulation allows the enterohepatic system to maintain a 
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homeostatic level of bile acids, drugs, and xenobiotics through feedback regulation that 
protects the body from potential toxic events.
Staudinger et al. Page 18














Model for the FXR-mediated feed-forward and feedback regulation effects on gene 
expression. Feed-forward regulation by FXR in the liver and intestine is mediated by bile-
acid activators of this NR superfamily member, primarily CA, and CDCA. Activated FXR, 
in turn, positively regulates the expression of FXR target genes that encode both drug- and 
bile-acid–transporter proteins OATP1B1, OATP1B3, OSTα/β, and BSEP. These transporter 
proteins function in the uptake and eventual elimination of drugs and bile acids from 
enterocytes and hepatocytes, hence the presence of excess bile acids in these tissues 
upregulates their own excretion and efflux. Feedback inhibition of primary bile-acid–uptake 
transporters ASBT and NTCP, in enterocytes and hepatocytes, respectively, is accomplished 
through a regulatory circuit that involves FXR-mediated induction of the expression and 
activity of SHP. The increased levels of the SHP nuclear receptor, which functions in a 
dominant-negative manner because of the lack of a functional DNA-binding domain, 
interacts with LRH-1 to repress the expression of genes encoding CYP7A1 and CYP8B1, 
enzymes centrally involved in the de novo production of additional bile acids from 
endogenous excess cholesterol. Increased SHP protein also represses the expression of its 
own gene through sequestration of LRH-1 from its own promoter. Thus, both synthesis of 
new bile acids from cholesterol, as well as uptake of old bile acids, is downregulated 
simultaneously to prevent the accumulation of excess bile acids in enterohepatic circulation.
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Model for the gut-liver axis that involves the FGF15/19-signaling mechanism. Endocrine 
actions of FGF15. Expression of the gene encoding FGF15 is induced in the small intestine 
by bile acids acting on the FXR/RXRα heterodimer. Subsequently, FGF15 is secreted into 
the enterohepatic circulation to act in an endocrine manner by binding a receptor on 
hepatocytes called FGFR4. The activated FGFR4 receptor signals the liver to repress 
CYP7A1 expression and activity. The CYP7A1 enzyme is the rate-limiting step in the 
synthesis of bile acids from cholesterol. In this manner, FGF15 (FGF19 in humans) 
suppresses de novo synthesis of bile acids from cholesterol through a mechanism that 
requires SHP. The extent to which this mechanism functions to downregulate drug-and bile-
acid–transporter proteins in hepatocytes is currently unknown, but is a likely fruitful area of 
future research.
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